Drug search by name

Soliris and Meningococcal infections

Result of checking the interaction of drug Soliris and disease Meningococcal infections for safety when used together.

Check result:

Soliris <> Meningococcal infections

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Eculizumab is contraindicated in patients with unresolved serious Neisseria meningitidis infection, in those who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying treatment outweigh the risks of developing a meningococcal infection. Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab. The use of eculizumab increases a patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis). Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if an infection is suspected. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. It is recommended to discontinue eculizumab in patients who are undergoing treatment for serious meningococcal infections.

Soliris

Generic Name: eculizumab

Brand Name: Soliris

Synonyms: n.a.

What is Soliris?